Countdown to Colgate-Palmolive (CL) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts forecast that Colgate-Palmolive (CL) will report quarterly earnings of $0.89 per share in its upcoming release, pointing to a year-over-year decline of 2.2%. It is anticipated that revenues will amount to $5.06 billion, exhibiting no change compared to compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.In light of this perspective, let's dive into the average estimates of certain Colgate-Palmolive metrics that are commonly tracked and forecasted by Wall Street analysts.The consensus estimate for 'Net Sales- Pet Nutrition' stands at $1.13 billion. The estimate indicates a change of +1.1% from the prior-year quarter.Analysts forecast 'Net Sales- Total Oral, Personal and Home Care' to reach $3.91 billion. The estimate indicates a year-over-year change of -0.9%.Analysts' assessment points toward 'Net Sales- Oral, Personal and Home Care- North America' reaching $1.01 billion. The estimate points to a change of +1% from the year-ago quarter.According to the collective judgment of analysts, 'Net Sales- Oral, Personal and Home Care- Latin America' should come in at $1.24 billion. The estimate points to a change of -2.5% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Net Sales- Oral, Personal and Home Care- Africa/Eurasia' of $277.30 million. The estimate indicates a change of +1.6% from the prior-year quarter.Analysts predict that the 'Net Sales- Oral, Personal and Home Care- Europe' will reach $716.03 million. The estimate indicates a year-over-year change of -0.6%.The consensus among analysts is that 'Net Sales- Oral, Personal and Home Care- Asia Pacific' will reach $666.60 million. The estimate points to a change of -2.3% from the year-ago quarter.Based on the collective assessment of analysts, 'Operating profit- Total Oral, Personal and Home Care' should arrive at $999.32 million. Compared to the current estimate, the company reported $1.06 billion in the same quarter of the previous year.The combined assessment of analysts suggests that 'Operating profit- Pet Nutrition' will likely reach $260.59 million. Compared to the present estimate, the company reported $235.00 million in the same quarter last year.Analysts expect 'Operating profit- Oral, Personal and Home Care- North America' to come in at $200.45 million. The estimate compares to the year-ago value of $223.00 million.It is projected by analysts that the 'Operating profit- Oral, Personal and Home Care- Latin America' will reach $364.91 million. Compared to the current estimate, the company reported $417.00 million in the same quarter of the previous year.The average prediction of analysts places 'Operating profit- Oral, Personal and Home Care- Africa/Eurasia' at $61.54 million. Compared to the present estimate, the company reported $64.00 million in the same quarter last year. View all Key Company Metrics for Colgate-Palmolive here>>> Shares of Colgate-Palmolive have experienced a change of -4.9% in the past month compared to the +3.6% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), CL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Higher. Faster. Sooner. Buy These Stocks NowA small number of stocks are primed for a breakout, and you have a chance to get in before they take off.At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We’ve combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month.You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days.Download the report free now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Colgate-Palmolive Company (CL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks